or
forgot password

Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Ulcerative Colitis, Colon Cancer

Thank you

Trial Information

Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer


Amino acids are being measured in colon tissues and in serum by HPLC. Cytokines and
chemokines are being measured in colon tissues and in serum by Luminex assay. Cytokines and
chemokines are also being measured in colon tissues by real-time PCR analysis of mRNA
expression.


Inclusion Criteria:



- 18 years of age or older

- Colonoscopy for one of the following: clinical indications, disease assessment, or
surveillance for dysplasia (as in ulcerative colitis)

- Screening for cancer

Exclusion Criteria:

- refusal to participate

- age less than 18 years at time of colonoscopy

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity

Outcome Time Frame:

24 months

Safety Issue:

No

Principal Investigator

Keith Wilson, MD, AGAF

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt University

Authority:

United States: Institutional Review Board

Study ID:

090943

NCT ID:

NCT01091558

Start Date:

September 2009

Completion Date:

Related Keywords:

  • Ulcerative Colitis
  • Colon Cancer
  • ulcerative colitis
  • colon cancer
  • endoscopy
  • screening
  • Colonic Neoplasms
  • Colitis
  • Colitis, Ulcerative
  • Ulcer

Name

Location
Vanderbilt Hospital Nashville, Tennessee  37232